Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4685-4692

  Disis, Mary L ^a   Wallace, Danelle R ^a   Gooley, Theodore A ^a   Dang, Yushe ^a   Slota, Meredith ^a   Lu, Hailing ^a   Coveler, Andrew L ^a   Childs, Jennifer S ^a   Higgins, Doreen M ^a   Fintak, Patricia A ^a   Dela Rosa, Corazon ^a   Tietje, Kathleen ^a   Link, John ^a   Waisman, James ^a   Salazar, Lupe G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CANCER VACCINE; MONOCLONAL ANTIBODY; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; METASTASIS; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; REGULATORY T LYMPHOCYTE; SIDE EFFECT; BLOOD; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; PAIN; PATHOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; FATIGUE; FEMALE; HEADACHE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; PAIN; PEPTIDES; RECEPTOR, ERBB-2; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; VACCINATION;

EID: 70350435441     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6789     Document Type: Article

References (28)

1. Knutson KL, Schiffman K, Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477-484, 2001
2. Le Bon A, Etchart N, Rossmann C, et al: Cross-priming of CD8+ T cells stimulated by virusinduced type I interferon. Nat Immunol 4:1009-1015, 2003
3. Castellino F, Germain RN: Cooperation between CD4+ and CD8+ T cells: When, where, and how. Annu Rev Immunol 24:519-540, 2006
4. Salazar LG, Coveler AL, Swensen RE, et al: Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol 125:275-280, 2007
5. Dang Y, Knutson KL, Goodell V, et al: Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 13:1883-1891, 2007
6. Disis ML, Gooley TA, Rinn K, et al: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624-2632, 2002
7. Disis ML, dela Rosa C, Goodell V, et al: Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 308:13-18, 2006
8. Maecker HT, Moon J, Bhatia S, et al: Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol 6:17, 2005
9. Pagano M, Gauvreau K: Principles of Biostatistics (ed 2). Pacific Grove, CA, Duxbury Press, 2000
10. Park KH, Goodell V, Higgins D, et al: Insulinlike growth factor binding protein 2 is an essential target for the immunomodulation of breast cancer. Cancer Res 68:8400-8409, 2008
11. Salazar LG, Fikes J, Southwood S, et al: Immunization of cancer patients with HER-2/neuderived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9:5559-5565, 2003
12. Lu H, Goodell V, Disis ML: Humoral immunity directed against tumor associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7:1388-1394, 2008
13. Bates GJ, Fox SB, Han C, et al: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373-5380, 2006
14. Tan AR, Alexe G, Reiss M: Transforming growth factor-beta signaling: Emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat [epub ahead of print on October 9, 2008]
15. Grau AM, Wen W, Ramroopsingh DS, et al: Circulating transforming growth factor-beta-1 and breast cancer prognosis: Results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 112: 335-341, 2008
16. Moutsopoulos NM, Wen J, Wahl SM: TGFbeta and tumors: An ill-fated alliance. Curr Opin Immunol 20:234-240, 2008
17. Wei S, Shreiner AB, Takeshita N, et al: Tumorinduced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res 68:5432-5438, 2008
18. Guarneri V, Lenihan DJ, Valero V, et al: Longterm cardiac tolerability of trastuzumab in metastatic breast cancer: The M. D. Anderson Cancer Center experience. J Clin Oncol 24:4107-4115, 2006
19. Disis ML, Knutson KL, Schiffman K, et al: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62:245-252, 2000
20. Taylor C, Hershman D, Shah N, et al: Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133-5143, 2007
21. Hueber W, Utz PJ, Steinman L, et al: Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 4:290-295, 2002
22. Vanderlugt CL, Miller SD: Epitope spreading in immune-mediated diseases: Implications for immunotherapy. Nat Rev Immunol 2:85-95, 2002
23. Dai YD, Carayanniotis G, Sercarz E: Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2:169-175, 2005
24. Harbers SO, Crocker A, Catalano G, et al: Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117:1361-1369, 2007
25. Hoos A, Parmiani G, Hege K, et al: A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1-15, 2007
26. Jackisch C: HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 11:34-41, 2006 (suppl 1)
27. Schaller G, Bangemann N, Weber J, et al: Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pretreated metastatic breast cancer. J Clin Oncol 23: 57s, 2005 (suppl; abstr 717)
28. Yamamoto D, Iwase S, Kitamura K, et al: A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Res Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 61:509-514, 2008